Uncategorized
Eylea approved for treatment of retinal vein occlusion in Japan
Bayer Yakuhin, Bayer HealthCare’s Japanese subsidiary, received approval for Eylea from the Ministry of Health, Labour and Welfare in Japan to treat patients with macular edema due to retinal vein occlusion, according to a press release from Regeneron.The new indication is for macular edema secondary to branch retinal vein occlusion. Eylea (aflibercept, Regeneron/Bayer) was previously approved for macular edema secondary to central retinal vein occlusion.